唑来膦酸对大鼠颌骨间充质干细胞成骨分化的影响

doi:10.3969/j.issn.1005-4979.2015.01.005

摘要/Abstract

摘要： 目的：研究唑来膦酸对大鼠颌骨来源的间充质干细胞增殖、成骨分化及成骨因子RANKL/OPG mRNA表达的影响。方法：体外培养新生SD大鼠颌骨来源的间充质干细胞，观察不同浓度（0、0.5、1.0、2.0、4.0、8.0 μg/mL）唑来膦酸对细胞增殖的影响。观察较高浓度唑来膦酸对细胞碱性磷酸酶活性、矿化结节形成以及成骨因子RANKL/OPG mRNA表达的影响。结果：唑来膦酸≥1.0 μg/mL能明显抑制细胞增殖，低浓度（0.5 μg/mL）则不影响细胞增殖，高浓度唑来膦酸（2.0 μg/mL）可抑制碱性磷酸酶活性、矿化结节的形成。高浓度唑来膦酸（2.0 μg/mL）能使颌骨间充质干细胞RANKL mRNA表达减少, OPG mRNA表达增加, 且明显下调成骨因子RANKL/OPG比率。结论：唑来膦酸在高浓度时明显抑制颌骨来源间充质干细胞的增殖和分化，并通过调节其表面RANKL/OPG mRNA表达，抑制破骨细胞的功能，骨生成与骨吸收同时减少，骨改建过程受抑制。

关键词: 唑来膦酸, 颌骨, 间充质干细胞, 增殖, 分化, RANKL/OPG, 大鼠

Abstract: Objective: To investigate the effect of zoledronic acid on the proliferation, osteogenic differentiation and the osteogenic factors RANKL/OPG mRNA expression of mandible mesenchymal stem cells(MSCs) in rats. Methods: The mesenchymal stem cells isolated from the mandible of SD rats, were cultured with different concentrations of zoledronic acid ranging from 0~8 μg/mL. At 3 days after zoledronic acid intervention, CKK-8 assay was used to measure the absorbance to detect the effect of zoledronic acid on the proliferation of mandible mesenchymal stem cells. Cell alkaline phosphatase activity, mineralized nodules formation, RANKL/OPG expression of MSCs in rats to zoledronic acid were analyzed. Results: Zoledronic acid at the concentration of ≥1.0 μg/mL could inhibit the proliferation of MSCs，but it had no effect at the concentration of 0.5 μg/mL. Zoledronic acid at the concentration of 2.0μg/mL could inhibit alkaline phosphatase activity, mineralized nodules formation of MMSCs. Zoledronic acid at the concentration of 2.0 μg/mL could down-regulate RANKL mRNA expression, but up-regulate OPG mRNA expression and down-regulate RANKL/OPG ratio. Conclusion: Zoledronic acid at high concentration can inhibit the proliferation and differentiation of MSCs. Whereas, it can inhibit the function of osteoclasts in bone remodeling by regulating the expression of MSCs cell-surface RANKL and OPG mRNA.

Key words: zoledronic acid, mandible, mesenchymal stem cells, proliferation, differentiation, RANKL/OPG, rats

中图分类号:

R782.1

龚雪，苏俭生. 唑来膦酸对大鼠颌骨间充质干细胞成骨分化的影响[J]. 《口腔颌面外科杂志》, 2015, 25(1): 28-.

GONG Xue, SU Jian-sheng. Cellular and Molecular Mechanisms of Action of Zoledronic Acid on Mandible Mesenchymal Stem Cells in Rats[J]. 《Journal of Oral and Maxillofacial Surgery》, 2015, 25(1): 28-.

https://journal06.magtech.org.cn/Jweb_joms/CN/Y2015/V25/I1/28

参考文献

[1] Eastell R, Walsh JS, Watts NB, et al. Bisphosphonates for postmenopausal osteoporosis[J]. Bone, 2011, 49(1):82-88.

[2] Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice[J]. Mayo Clin Proc, 2008, 83(9):1032-1045.

[3] Reid IR, Lyles K, Su G, et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years[J]. J Bone Miner Res, 2011, 26(9):2261-2270.

[4] Biswas PN, Wilton LV, Shakir SA. Pharmacovigilance study of alendronate in England[J]. Osteoporos Int, 2003, 14(6):507-514.

[5] Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation[J]. N Engl J Med, 2007, 356(18):1895-1896.

[6] Colella G, Campisi G, Fusco V. American association of oral and maxillofacial surgeons position paper: bisphosphonate-related osteonecrosis of the jaws-2009 update: the need to refine the BRONJ definition[J]. J Oral Maxillofac Surg, 2009, 67(12):2698-2699.

[7] Pazianas M, Abrahamsen B. Safety of bisphosphonates[J]. Bone, 2011, 49(1):103-110.

[8] Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9):1115-1117.

[9] Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases[J]. J Oral Maxillofac Surg, 2004, 62(5):527-534.

[10] Coleman R, Burkinshaw R, Winter M, et al. Zoledronic acid[J]. Expert Opin Drug Saf, 2011, 10(1):133-145.

[11] Hasegawa T, Ri S, Umeda M, et al. The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy[J]. J Craniomaxillofac Surg, 2013, 16(12):1-6.

[12] 陈菊仙, 郭雪华, 阮宏. 唑来膦酸并发的上颌骨坏死2例报告[J]. 口腔颌面外科杂志, 2012, 22(5):378-380.

[13] Kavanagh KL, Guo K, Dunford JE, et al.The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs[J]. Proc Natl Acad Sci U S A, 2006, 103(20):7829-7834.

[14] Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy[J]. Cancer, 2005, 104(1):83-93.

[15] Abu-Id MH, Warnke PH, Gottschalk J, et al. "Bisphossy jaws"-high and low risk factors for bisphosphonate iduced osteonecrosis of the jaw[J]. J Craniomaxillofac Surg, 2008, 36(2):95-103.

[16] 赵航, 苏俭生. 双膦酸盐致相关性颌骨坏死的研究进展[J]. 口腔颌面外科杂志, 2013, 23(1):72-76.

[17] Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates[J]. Cancer, 2000, 88(12Suppl): 2961-2978.

[18] Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment[J]. Semin Oncol, 2001, 28 (2Suppl 6):35-44.

[19] Idris AI, Rojas J, Greig IR, et al. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro[J]. Calcif Tissue Int, 2008, 82(3):191-201.

[20] Im GI, Qureshi SA, Kenney J, et al. Osteoblast proliferation and maturation by bisphosphonates[J]. Biomaterials, 2004, 25(18):4105-4115.

[21] Pan B, To LB, Farrugia AN, et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro[J]. Bone, 2004, 34(1):112-123.

[22] Orriss IR, Key ML, Colston KW, et a1. Inhibition of osteoblast function in vitro by aminobisphosphonates[J]. J Cell Biochem, 2009, 106(1):109-118.

[23] Stresing V, Fournier PG, Bellahcène A, et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase[J]. Bone, 2011, 48(2):259-266.

[24] Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength[J]. Curr Opin Pharmacol, 2005, 5(6):618-625.

[25] Takahashi N1, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function[J]. Biochem Biophys Res Commun, 1999, 256(3):449-455.

[26] Alhadlaq A, Mao JJ. Mesenchymal stem cells: isolation and therapeutics[J]. Stem Cells Dev, 2004, 13(4):436-448.

[27] Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease[J]. N Engl J Med, 2002, 347(3):175-184.

选择文件类型/文献管理软件名称

选择包含的内容